Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).

ABSTRACT: Rationale: Peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumors (NETs) has been explored for more than two decades, but there are only limited data on the treatment of NETs of unknown primary site (CUP-NETs). This study aimed to analyze the long-term outcome, efficacy, and safety of PRRT in patients with CUP-NETs. Methods: Patients with pathologically confirmed metastatic CUP-NET who received lutetium-177 (¹⁷⁷Lu) and/or yttrium-90 (⁹⁰Y) labeled somatostatin analogs between March 2001 and March 2019 were retrospectively reviewed; those patients were referred as cCUP-NETs (clinical CUP-NETs). Eighty-one patients had unknown primary tumors even after [⁶⁸Ga]Ga-SSTR and [¹⁸F]FDG PET/CT and were classifi

SUBMITTER: Baum RP 

PROVIDER: S-EPMC10750196 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature